Post-allo cyclophosphamide now is a well-established prophylaxis for graft-versus-host disease, both acute and chronic. It has been established first in patients that receive a transplantation from a haploidentical donor, but now it is used also for patients with mismatch-unrelated donors, but also match-related and unrelated donors. It’s very successful. We still need to remain cautious because there is some toxicity, some cardiac toxicity, also some infectious complications...
Post-allo cyclophosphamide now is a well-established prophylaxis for graft-versus-host disease, both acute and chronic. It has been established first in patients that receive a transplantation from a haploidentical donor, but now it is used also for patients with mismatch-unrelated donors, but also match-related and unrelated donors. It’s very successful. We still need to remain cautious because there is some toxicity, some cardiac toxicity, also some infectious complications. So now the field is moving to see if we can use lower doses of post-transplant cyclophosphamide with some studies that have been done, some pilot study, but also some future randomized study to evaluate lower doses of post-transplant cyclophosphamide to see if this is still as effective but with less toxicity. So I really think that PTCy is what we use today. This is also the future of the GvHD prophylaxis but with refinement regarding its use.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
